pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·11h ago·1 min read
save

Medicare advances ACCESS pilot but leaves patients unaware of participating providers

Aug 6, 2026·read at STAT ↗RegulatoryNeutral

STAT's Health Tech newsletter reports that Medicare is promoting its ACCESS chronic‑care pilot, yet patients cannot see which providers are offering the program.

A one‑month progress check highlights the communication gap, noting that while the initiative is being pushed, information about participating clinicians remains unavailable to beneficiaries.

The piece also notes that health regulators are actively courting industry stakeholders to shape forthcoming AI regulations, underscoring a broader focus on technology oversight in health care.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Medicare pushes ACCESS but doesn’t tell patients what providers offer it”

read at STAT ↗
434 words · retrieved 10h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Psychiatry & CNS2

related stories

  • Apr 27STAT+: Astellas retries XLMTM gene therapy after deathsSTAT
  • Apr 27What’s the true risk for eating disorders with GLP-1s?STAT
  • Apr 27STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trialSTAT
  • Apr 27STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage studySTAT
  • Apr 27STAT+: Veradermics’ hair loss drug succeeds in late-stage trialSTAT